| Literature DB >> 27095644 |
Amisha Wallia1, Vidhya Illuri1, Mark E Molitch2.
Abstract
Patients who undergo solid organ transplantation may have preexisting diabetes mellitus (DM), develop new-onset DM after transplantation (NODAT), or have postoperative hyperglycemia that resolves shortly after surgery. Although insulin is usually used to control hyperglycemia in the hospital, following discharge most of the usual diabetes oral and parenteral medications can be used in treatment. However, when there are comorbidities such as impaired kidney or hepatic function, or heart disease, special precautions may be necessary. In addition, drug-drug interactions, such as drugs interacting with CYP3A4 enzyme pathway, require additional consideration because of possible interaction with immunosuppressive drug metabolism.Entities:
Keywords: Diabetes; Immunosuppression; Insulin; Kidney; Liver; NODAT; Transplant; Transplantation
Mesh:
Substances:
Year: 2016 PMID: 27095644 DOI: 10.1016/j.mcna.2016.01.005
Source DB: PubMed Journal: Med Clin North Am ISSN: 0025-7125 Impact factor: 5.456